Combination Prevention

Expanded high-impact prevention is needed to bring the epidemic to a conclusive end.

Combination or high-impact prevention is a set of strategically-selected interventions that matches the needs of a given country or community—and is delivered at the scale needed to make an impact. It means doing less of something and far more of others. It means making tough decisions and measuring impact. Above all, it means moving with clarity and speed.

There are emerging global definitions of what combination prevention is, and evolving models of what it can achieve. AVAC works with advocates to define what combination prevention means in a given context, track country and donor alignment with a combination prevention strategy and ensure that there is an implementation science agenda to fill in gaps in knowledge. To learn more about combination prevention in general and our work in particular visit the links below:

Ongoing Combination Prevention Trials — A map of several studies ongoing that seek to measure the impact of various prevention packages.
Core Activities for an Effective AIDS Response — A graphic illustration of the key interventions for a high impact response.
Invest Now to Save Lives and Funds — A graphic showing the impact of increased investment in core interventions—today.

What We're Reading

Trial Designs for Evaluating Combination HIV Prevention Approaches

The multi-arm design is useful for evaluating single factor regimens, while the all-in-one and factorial designs are sensitive in assessing the overall efficacy when there is interest in combining individual component regimens anticipated to have complementary mechanisms. The factorial design is a preferred approach when assessing combination regimens due to its favorable power properties and since it is the only design providing direct insights about the contribution of individual components to the combination approach’s overall efficacy and about potential interactions.

July 23, 2020

Combination Prevention, Male and Female Condoms, PrEP, Treatment

HIV Research & Clinical Practice

Featured Resources

AVAC Report 2019: Now What?

At the threshold of 2020, it’s clear that global goals for HIV prevention will miss the mark by a long shot. Though important progress has been made, the crisis UNAIDS called out in 2016 persists today with new infections around 1.7 million annually, a far cry from the 2020 target of fewer than 500,000. So, we asked ourselves, Now What?, and answered with cross-cutting analysis and an advocacy agenda to match.

November 2019

AVAC

HIV Vaccine, Combination Prevention, Male and Female Condoms, Cure, Hormonal Contraceptives and HIV, Microbicides, Multipurpose Prevention Technologies, PrEP, Treatment, Voluntary Medical Male Circumcision

AVAC Report

Our infographics are clear, accessible tools for conveying complex concepts to new audiences, including policy makers and funders.

On the Blog

The Curtain Raises on R4P: Findings on the AMP Trials and more...

At an HIV R4P conference, research teams presented a range of data from ongoing studies of antibody-mediated prevention, long-acting injectable PrEP, a monthly PrEP pill, and trends in daily oral PrEP use.

January 26, 2021

, Combination Prevention, Microbicides, PrEP

AVAC Report 2019: With 2020 targets sure to be missed, we ask Now What?

AVAC released Now What?, our 2019 annual report on the state of the HIV prevention field. Each year, the AVAC Report frames the most pressing advocacy issues facing the HIV response. At the threshold of 2020, it’s clear that global goals for HIV prevention will miss the mark by a long shot.

November 21, 2019

, HIV Vaccine, Combination Prevention, Male and Female Condoms, Microbicides, Multipurpose Prevention Technologies, PrEP, Therapeutic Vaccines, Treatment, Voluntary Medical Male Circumcision